Renatus, a company specializing in cholesterol modulators, announced on March 21 that it has been selected for a national research project funded by the Korea Dementia Research Center (KDRC). This project will be conducted through a consortium between Ajou University School of Medicine and Renatus.

The KDRC program supports step-by-step research and development efforts for dementia-related treatments in South Korea. Established in August 2020, it is set to provide KRW 198.7 billion in funding over eight years, through 2028.

Professor Sun Ah Park from the Department of Neurology at Ajou University School of Medicine, the principal investigator of this project, stated, “Emerging evidence suggests that abnormal cholesterol metabolism plays a critical role in the development and progression of Alzheimer’s disease. Disruption of cholesterol homeostasis in the brain is thought to facilitate the aggregation and propagation of beta-amyloid (Aβ) and tau proteins across neighboring regions. The impaired clearance of these pathological proteins contributes to the destruction of neurons and neural networks."

Heegon Kim, CEO of Renatus and co-research leader, commented, "Our studies in zebrafish and mouse models of Alzheimer’s disease have shown that cholesterol modulators improve cognitive function and reduce pathogenic proteins. Through this project, we will optimize cholesterol modulators to develop an innovative treatment that addresses the root cause of Alzheimer's disease."

Ajou University and Renatus will receive approximately KRW 900 million in total funding over three years from KDRC.

To keep updated, please follow:

LinkedIn Page: https://www.linkedin.com/company/renatustx/ 

About RENATUS

Renatus is a pharma company thriving to develop next generation cyclodextrins to provide safe treatment options for patients living with cholesterol-associated diseases. Renatus seeks to provide critical impact in developing translational cyclodextrin therapies and fulfill its vision to protect the world from various cholesterol-associate diseases. For more information, please visit www.renatustx.com